PembroX: Enhancing the Immunogenicity of Non-Small Cell Lung Cancer With Pembrolizumab +/- Stereotactic Radiotherapy Delivered in the Preoperative Window, A Randomized Phase II Study With Correlative Biomarkers
Phase of Trial: Phase II
Latest Information Update: 12 Feb 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacodynamics
- Acronyms PembroX
- 03 Feb 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2017 Planned End Date changed from 18 Jul 2021 to 1 Sep 2021.